Close Menu

NEW YORK – Evercore ISI downgraded shares of Twist Bioscience to an In-Line rating on Monday, setting a price target of $140.

"We don't debate that Twist is one of the more exciting companies under coverage," Evercore analyst Vijay Kumar and colleagues wrote in a research note, adding that the firm's fiscal year 2021 revenue guidance is conservative. "That said, key new growth verticals will take time to develop," they wrote, namely the firm's biopharma and DNA-based data storage businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.